


Novel immunotherapy technology


"First-in-class immunotherapy treatment for lung cancer"

Non-small cell lung cancer (NSCLC) makes up 85% of all lung malignancies with an estimated 230.000 new cases and 135.000 deaths in 2020 (US) – accounting for ~25% of all cancer deaths. We aim to develop a novel treatment for NSCLC based on our immunotherapy (BiCE) platform



- Bi-specific nanobodies can be used to recruit the complement system to the surface of cancer cells (left)
- Activation of the innate immune system by BiCE085 induces tumour cell killing (right)
- Modular platform - nanobodies can easily be exchanged and combined in multiple ways

Killing of EGFR-positive cancer cells in human blood



Technology Description

We have developed a novel technology to harness the power of the innate immune system and will use this technology to develop a new type of immunotherapy targeting EGFR for treatment of NSCLC. Our technology is based on bispecific nanobodies that effectively recruit part of the innate immune system (called the complement system) to the surface of cancer cells. We have termed these molecules Bi-specific Complement Engagers (BiCEs).

Intellectual Property Rights

WO 2019/238674 A1, PCT application filed in 2018

Team



PhD, Nick Stub Laursen
Inventor and Scientific Development



PhD, Dennis Pedersen
Drug Discovery



PhD, Heidi Gytz Olesen
In-vitro Biology



PhD, Mikael Winkler
Protein Chemistry



PhD, Peter Birk
Business Development

Current State

We have shown in vitro that our molecules are superior to approved monoclonal antibodies. We now want to show in vivo efficacy in a cancer mouse model.

Business opportunity and Call to action

We are looking for investors to help generate in-vivo proof of concept.

The current goal is to form a spin-out company by 2021

